<DOC>
	<DOCNO>NCT00208728</DOCNO>
	<brief_summary>During open-heart surgery , blood flow support heart-lung machine pump blood give oxygen . A problem associate heart-lung machine damage blood cause protein blood cell stick side heart-lung machine tubing . This breakdown blood cell affect platelet , help blood clot . Use un-treated circuit phase within next year , new technology available . The use coat tube show decrease problem post-operative bleed adult population . No study do pediatric population . We plan perform prospective , randomize study use un-treated circuit use , `` Smart '' circuit tube manufacture Cobe Cardiovascular Inc. , Arvada , CO PMEA circuit manufacture Terumo Corporation , Tokyo , Japan . Randomization perform perfusionist ( person run heart-lung machine ) charge case . No one else aware circuit use . There change operation heart-lung machine , anesthesia surgery study . Blood test standard care additional test perform small amount blood drawn . patient via arterial line . Additional blood stick require obtain sample .</brief_summary>
	<brief_title>Cardiopulmonary Circuits Pediatric Population</brief_title>
	<detailed_description>The goal study compare PC/SMART PMEA treat circuit current clinical standard ( untreated ) circuit regard blood component damage CPB . Specific Aims SA1 : To determine surface modify circuit decrease platelet activation , platelet sequestration , fibrinolysis pediatric cardiac surgery use CPB . Hypothesis 1 : Use surface modify circuit attenuate CPB relate decrease platelet count , diminish platelet dysfunction measure thromboelastography ( TEG ) , decrease fibrinolysis measure fibrin-split product level TEG . SA2 : To determine whether use surface modify circuit pediatric cardiac surgery result clinically relevant decrease post-operative coagulopathy measure post-operative bleeding blood product use . Hypothesis 2 : The use surface modify circuit result improve function coagulation system yield less post-operative bleeding thus few blood product transfusion . Methods The study prospective , randomize trial total 90 patient ( 5-10 kg ) undergo first time cardiac surgery use CPB Egleston Hospital randomize 3 group . Group 1 control group current standard unmodified CPB circuit use . Group 2 undergo surgery use PC/SMART modify CPB circuit ( Cobe Cardiovascular Inc , Arvada , CO ) . Group 3 undergo surgery use PMEA modify circuit ( Terumo Corporation , Tokyo , Japan ) . Hypothesis 1 test use follow assay : Total platelet count Hematocrit Prothrombin time ( PT ) Activated thromboplastin time ( aPTT ) Fibrin split-product level D-dimer level thromboglobulin level ( ELISA assay ) Thromboelastography ( TEG ) use heparinase ( eliminate heparin effect ) without REOPRO ( GPIIb/IIIa platelet inhibitor ) measure relative contribution platelet function fibrinogen activity clot formation Performed follow time-points : T1 = induction anesthesia , prior CPB T2 = 5 minute initiation CPB T3 = end re-warming ( end CPB ) T4 = post-bypass ( five minute protamine administration ) T5 = within 24 hour surgery ( TEG collect time ) Hypothesis 2 test quantify chest-tube drainage blood product administration ( red blood cell , platelet , fresh frozen plasma , cryoprecipitate ) first 12 hour wean CPB .</detailed_description>
	<criteria>patient electively schedule first time cardiac surgery require cardiopulmonary bypass weight 5 kg 10 kg sign informed consent patient require emergent cardiac surgery patient undergone prior cardiothoracic surgery document coagulation disorder use anticoagulant drug antiplatelet agent within 48 hour surgery patient require 4 hour CPB require return CPB inform consent obtain .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>pediatric</keyword>
	<keyword>congenital heart disease</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>